Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2401 - 2500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2401 | 26691907 |
US |
16 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2402 | 26691913 |
US |
9 | 2 |
Dermatitis atopic, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 2403 | 26691915 |
US |
42 | 1 |
Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, |
||||
| 2404 | 26691946 |
US |
56 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2405 | 26691947 |
US |
17 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2406 | 26691951 |
US |
2 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2407 | 26691973 |
US |
39 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2408 | 26691975 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2409 | 26691976 |
US |
30 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2410 | 26691983 |
US |
25 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2411 | 26691984 |
US |
27 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2412 | 26691985 |
US |
62 | 2 |
Dermatitis atopic, Pruritus, Rash pruritic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2413 | 26692039 |
US |
18 | 2 |
Dermatitis atopic, Rash, Dry skin, |
||||
DUPILUMAB, |
||||
| 2414 | 26692084 |
US |
28 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, OFATUMUMAB, |
||||
| 2415 | 26693244 |
US |
93 | |
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2416 | 26693299 |
US |
||
Quality of life decreased, Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2417 | 26694819 |
US |
24 | |
Dermatitis exfoliative generalised, Dermatitis atopic, Pain, Pruritus, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2418 | 26682773 |
US |
52 | 2 |
Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2419 | 26682789 |
US |
71 | 1 |
Pruritus, Rash, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2420 | 26682840 |
US |
29 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2421 | 26682843 |
US |
2 | |
Dermatitis atopic, Pruritus, Erythema, |
||||
DUPILUMAB, |
||||
| 2422 | 26682847 |
US |
32 | 2 |
Rash pruritic, Rash erythematous, Dermatitis atopic, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 2423 | 26682860 |
US |
2 | |
Sensitivity to weather change, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2424 | 26682863 |
US |
4 | 2 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, Rash, |
||||
DUPILUMAB, |
||||
| 2425 | 26682884 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2426 | 26682890 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2427 | 26682891 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2428 | 26682899 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2429 | 26682903 |
US |
41 | 2 |
Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2430 | 26682950 |
US |
4 | 1 |
Rash erythematous, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2431 | 26683021 |
US |
2 | |
Dermatitis atopic, Injection site pain, Drug ineffective, |
||||
DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, COPPER, CUPRIC CHLORIDE, DULOXETINE HYDROCHLORIDE, DULOXETINE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, MAGNESIUM CITRATE, MAJOR MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, CVS MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - LEMON, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, MAGNESIUM CITRATE ORAL SOLUTION, EPIC MEDICAL MAGNESIUM CITRATE ORAL SOLUTION - LEMON, CVS MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, CVS MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - LEMON, LEADER MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, BE HEALTH MAGNESIUM CITRATE ORAL SOLUTION - LEMON, EQUATE MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, FRESKARO MAGNESIUM CITRATE ORAL SOLUTION - CHERRY, LEADER MAGNESIUM CITRATE ORAL SOLUTION - GRAPE, HARRIS TEETER MAGNESIUM CITRATE ORAL SOLUTION - LEMON, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PERFLUOROHEXYLOCTANE, NEMOLIZUMAB-ILTO, PIMECROLIMUS, SULFACETAMIDE SODIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, CYCLOSPORINE, VITAMIN C, TIRZEPATIDE, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 2432 | 26683044 |
US |
69 | 1 |
Irritability, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2433 | 26683048 |
US |
13 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2434 | 26683049 |
US |
19 | 2 |
Alopecia, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2435 | 26683106 |
US |
1 | |
Blindness transient, Dermatitis atopic, Confusional state, Herpes zoster, Adverse drug reaction, Back pain, Hypertension, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 2436 | 26683119 |
US |
22 | 2 |
Dermatitis atopic, Rash, Skin discomfort, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 2437 | 26683120 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2438 | 26683127 |
US |
23 | 1 |
Dermatitis atopic, Skin haemorrhage, Skin weeping, Pruritus, Dry skin, Skin exfoliation, Product dose omission issue, |
||||
DUPILUMAB, ALBUTEROL SULFATE, EPINEPHRINE, ADRENALINUM, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, CETIRIZINE HYDROCHLORIDE, |
||||
| 2439 | 26683140 |
US |
47 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 2440 | 26683155 |
US |
1 | |
Attention deficit hyperactivity disorder, Condition aggravated, Depression, Dermatitis atopic, Rash erythematous, Dry skin, Pruritus, Eyelid rash, Rash, Therapeutic response decreased, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2441 | 26683202 |
US |
17 | 2 |
Dermatitis atopic, Therapeutic response shortened, Off label use, |
||||
DUPILUMAB, |
||||
| 2442 | 26683207 |
US |
2 | |
Dermatitis atopic, Paraesthesia, |
||||
DUPILUMAB, |
||||
| 2443 | 26683220 |
US |
62 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2444 | 26683235 |
US |
35 | 2 |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2445 | 26683245 |
US |
46 | 2 |
Blister, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2446 | 26683276 |
US |
78 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2447 | 26683283 |
US |
27 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2448 | 26683286 |
US |
28 | 1 |
Dermatitis atopic, Rash, Dry skin, |
||||
DUPILUMAB, |
||||
| 2449 | 26683293 |
US |
42 | 2 |
Dermatitis atopic, Pruritus, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 2450 | 26683301 |
US |
43 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2451 | 26683310 |
US |
47 | 2 |
Rash, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2452 | 26683350 |
US |
1 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2453 | 26683388 |
US |
19 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2454 | 26683398 |
US |
25 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2455 | 26683418 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2456 | 26683456 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2457 | 26683469 |
US |
25 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, TRALOKINUMAB-LDRM, |
||||
| 2458 | 26683473 |
US |
22 | 2 |
Cough, Sneezing, Dysphonia, Dermatitis atopic, Therapeutic response shortened, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2459 | 26683474 |
US |
15 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2460 | 26683478 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2461 | 26683494 |
US |
50 | 2 |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 2462 | 26683498 |
US |
1 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2463 | 26683501 |
US |
68 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2464 | 26683505 |
US |
63 | 2 |
Intertrigo, Injection site pain, Dermatitis atopic, Therapeutic response shortened, Pain, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2465 | 26683506 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2466 | 26683508 |
US |
42 | 2 |
Pharyngeal swelling, Pyrexia, Asthma, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2467 | 26683550 |
US |
5 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2468 | 26683555 |
US |
19 | 2 |
Dermatitis atopic, Rash, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2469 | 26683556 |
US |
59 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2470 | 26683559 |
US |
74 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2471 | 26683563 |
US |
63 | 2 |
Eczema nummular, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2472 | 26683565 |
US |
57 | 2 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 2473 | 26683574 |
US |
48 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2474 | 26683575 |
US |
41 | 2 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 2475 | 26683577 |
US |
25 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2476 | 26683581 |
US |
33 | 2 |
Eczema, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2477 | 26683585 |
US |
7 | 2 |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 2478 | 26683586 |
US |
18 | 1 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, Dermatitis atopic, Erythema, Swelling face, Circumoral swelling, Periorbital swelling, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2479 | 26683636 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2480 | 26683745 |
US |
26 | 1 |
Dermatitis atopic, Arthralgia, |
||||
DUPILUMAB, |
||||
| 2481 | 26683770 |
US |
80 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2482 | 26683779 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2483 | 26683798 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2484 | 26683801 |
US |
57 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2485 | 26683809 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2486 | 26683821 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2487 | 26683883 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2488 | 26683890 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2489 | 26684595 |
US |
1 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2490 | 26684596 |
US |
7 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2491 | 26684607 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2492 | 26684608 |
US |
29 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2493 | 26684682 |
US |
10 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2494 | 26684688 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2495 | 26684797 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2496 | 26684800 |
US |
9 | 1 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 2497 | 26684803 |
US |
66 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2498 | 26684807 |
US |
57 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2499 | 26684812 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2500 | 26684858 |
US |
24 | 1 |
Dermatitis atopic, Product dose omission issue, Dry skin, Photosensitivity reaction, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30